Overview

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

Status:
Withdrawn
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients. Interest in developing CNI-free regimens using other agents such as the proliferation signal inhibitor everolimus.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Calcineurin Inhibitors
Everolimus
Sirolimus
Tacrolimus